Intro to COVID-19: Drug Issues
This session will address a variety of issues relevant to the drug space, including current authorizations, conditions for authorization, supply chain challenges and shortages, the Coronavirus Treatment Acceleration Program (CTAP), and Operation Warp Speed.
Cathy L. Burgess, Partner, Alston & Bird LLP, Member, FDLI Board of Directors
This session was recorded as part of FDLI’s virtual course, “COVID-19: Introduction to FDA’s Existing Legal Authorities and Emerging Issues” on August 19, 2020.
- +$100 for nonmembers
Legal issues regarding the response to COVID-19 is a rapidly evolving field. It is important to note the program recording date given that FDA guidance may have revised or been updated. For questions, please check the FDA website at: https://www.fda.gov/home
Virtual Learning FAQ